Trump New Executive Orders Could Impact Indian Pharma Exports
News: President Donald Trump’s recent executive orders prioritize domestic pharmaceutical manufacturing in the U.S., posing major challenges for Indian drug exporters, especially in the generics market, according to a Nuvama Research report.
The move aims to re-shore production of APIs, KSMs, and raw materials, potentially disrupting global drug supply chains and reducing India’s cost advantage.
The orders also propose faster U.S. regulatory clearances, stricter compliance for foreign facilities, and higher fees for overseas manufacturers.
A possible requirement to disclose API origins could expose India’s reliance on Chinese imports, adding to scrutiny.
These measures reflect a broader focus on U.S. biosecurity and may significantly restructure the U.S. generics supply chain if fully implemented.
Source: The Economic Times
Join The Community
Recent News
-
Logistics & Industrial Leasing in India Surges to 30.7 MSF in H1 2025 -
Integrated Logistics Plan Launched in 8 Cities by Piyush Goyal to Cut Costs -
4 Round of India–New Zealand FTA Negotiations Scheduled for October -
India Highlights Net-Zero Supply Chain Goals at CII Global Summit -
India Must Lower Tariffs to ASEAN Standards, Says Adviser to PM
2 Comments